Found: 45
Select item for more details and to access through your institution.
Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 9, p. 1127, doi. 10.1111/jvh.13132
- By:
- Publication type:
- Article
A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured).
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 10, p. 1088, doi. 10.1002/cpdd.1454
- By:
- Publication type:
- Article
Development of sofosbuvir for the treatment of hepatitis C virus infection.
- Published in:
- Annals of the New York Academy of Sciences, 2015, v. 1358, n. 1, p. 56, doi. 10.1111/nyas.12832
- By:
- Publication type:
- Article
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 6, p. 675, doi. 10.1111/jvh.13079
- By:
- Publication type:
- Article
Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 7, p. 732, doi. 10.1002/jcph.253
- By:
- Publication type:
- Article
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 2, p. 217, doi. 10.1007/s00228-018-2576-4
- By:
- Publication type:
- Article
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study.
- Published in:
- Health Science Reports, 2020, v. 3, n. 2, p. 1, doi. 10.1002/hsr2.145
- By:
- Publication type:
- Article
Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 10, p. 1791, doi. 10.1111/cts.13581
- By:
- Publication type:
- Article
An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin.
- Published in:
- Clinical Case Reports, 2017, v. 5, n. 4, p. 371, doi. 10.1002/ccr3.841
- By:
- Publication type:
- Article
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
- Published in:
- Viruses (1999-4915), 2023, v. 15, n. 10, p. 2026, doi. 10.3390/v15102026
- By:
- Publication type:
- Article
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
- Published in:
- Viruses (1999-4915), 2018, v. 10, n. 9, p. 462, doi. 10.3390/v10090462
- By:
- Publication type:
- Article
Interferon γ–Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response.
- Published in:
- Journal of Infectious Diseases, 2014, v. 210, n. 12, p. 1881, doi. 10.1093/infdis/jiu325
- By:
- Publication type:
- Article
The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study.
- Published in:
- BMC Gastroenterology, 2005, v. 5, p. 14, doi. 10.1186/1471-230X-5-14
- By:
- Publication type:
- Article
Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti.
- Published in:
- BMC Gastroenterology, 2004, v. 4, p. 31, doi. 10.1186/1471-230X-4-31
- By:
- Publication type:
- Article
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 4, p. 628, doi. 10.1093/cid/ciz243
- By:
- Publication type:
- Article
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B.
- Published in:
- Antiviral Therapy, 2022, v. 27, n. 6, p. 1, doi. 10.1177/13596535221127848
- By:
- Publication type:
- Article
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
- Published in:
- 2016
- By:
- Publication type:
- journal article
1850-P: High Prevalence of Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH): The Impact on Patient-Reported Outcomes (PROs).
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1850-P
- By:
- Publication type:
- Article
1449-P: The Enhanced Liver Fibrosis (ELF) Score Predicts Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1449-P
- By:
- Publication type:
- Article
1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1876-P
- By:
- Publication type:
- Article
The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction‐Associated steatotic Liver Disease (MASLD)—A randomised, double‐blind, placebo‐controlled, parallel‐group clinical trial (PUVENAFLD).
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 5, p. 552, doi. 10.1111/apt.18149
- By:
- Publication type:
- Article
Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 9, p. 1169, doi. 10.1111/apt.16830
- By:
- Publication type:
- Article
A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
- Published in:
- PLoS ONE, 2013, v. 8, n. 5, p. 1, doi. 10.1371/journal.pone.0063818
- By:
- Publication type:
- Article
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2016, v. 15, n. 6, p. 834, doi. 10.5604/16652681.1222098
- By:
- Publication type:
- Article
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42398-w
- By:
- Publication type:
- Article
Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1142, doi. 10.1002/cpdd.1339
- By:
- Publication type:
- Article
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
- Published in:
- Clinical Infectious Diseases, 2016, v. 62, n. 1, p. 32, doi. 10.1093/cid/civ722
- By:
- Publication type:
- Article
Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials.
- Published in:
- Clinical Infectious Diseases, 2014, v. 59, n. 12, p. 1666, doi. 10.1093/cid/ciu697
- By:
- Publication type:
- Article
Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study.
- Published in:
- Clinical Infectious Diseases, 2014, v. 58, n. 7, p. 960, doi. 10.1093/cid/ciu009
- By:
- Publication type:
- Article
A Pilot Study of Interleukin-11 in Subjects with Chronic Hepatitis C and Advanced Liver Disease Nonresponsive to Antiviral Therapy.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2004, v. 99, n. 12, p. 2359, doi. 10.1111/j.1572-0241.2004.40047.x
- By:
- Publication type:
- Article
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
- Published in:
- Liver International, 2024, v. 44, n. 4, p. 966, doi. 10.1111/liv.15816
- By:
- Publication type:
- Article
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
- Published in:
- Liver International, 2020, v. 40, n. 5, p. 1032, doi. 10.1111/liv.14320
- By:
- Publication type:
- Article
Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials.
- Published in:
- Liver International, 2020, v. 40, n. 4, p. 778, doi. 10.1111/liv.14266
- By:
- Publication type:
- Article
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
- Published in:
- Liver International, 2019, v. 39, n. 11, p. 2082, doi. 10.1111/liv.14209
- By:
- Publication type:
- Article
Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib.
- Published in:
- Liver International, 2018, v. 38, n. 10, p. 1849, doi. 10.1111/liv.13706
- By:
- Publication type:
- Article
Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens.
- Published in:
- Liver International, 2018, v. 38, n. 5, p. 821, doi. 10.1111/liv.13596
- By:
- Publication type:
- Article
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir ( FOURward study).
- Published in:
- Liver International, 2017, v. 37, n. 6, p. 836, doi. 10.1111/liv.13335
- By:
- Publication type:
- Article
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
- Published in:
- Liver International, 2016, v. 36, n. 2, p. 189, doi. 10.1111/liv.12964
- By:
- Publication type:
- Article
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
- Published in:
- Liver International, 2015, v. 35, n. 2, p. 448, doi. 10.1111/liv.12703
- By:
- Publication type:
- Article
Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function.
- Published in:
- Pharmacology Research & Perspectives, 2024, v. 12, n. 4, p. 1, doi. 10.1002/prp2.1213
- By:
- Publication type:
- Article
Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects.
- Published in:
- Journal of Gastroenterology & Hepatology, 2014, v. 29, n. 8, p. 1574, doi. 10.1111/jgh.12632
- By:
- Publication type:
- Article
Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
- Published in:
- PLoS ONE, 2018, v. 13, n. 8, p. 1, doi. 10.1371/journal.pone.0202226
- By:
- Publication type:
- Article
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
- Published in:
- Virology Journal, 2018, v. 15, p. 1, doi. 10.1186/s12985-018-0936-4
- By:
- Publication type:
- Article